Jefferies analyst Raj Denhoy reiterated a Buy rating on Orthofix (NASDAQ: OFIX) yesterday and set a price target of $69. The company’s shares closed yesterday at $61.87, close to its 52-week high of $61.98.
According to TipRanks.com, Denhoy is a top 100 analyst with an average return of 20.3% and a 71.7% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Edwards Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Orthofix with a $65.67 average price target, which is a 6.1% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $66 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $61.98 and a one-year low of $46.02. Currently, Orthofix has an average volume of 144.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Orthofix Medical, Inc. engages in the research, development, and market of orthopedic solutions. It operates through the following business segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The BioStim segment produces and sells devices for bone fusion enhancement in cervical and lumbar spine through the pulsed electromagnetic technology.
